Last update 15 Jul 2024

Recombinant Human Endostatin (Simcere)

Overview

Basic Info

Drug Type
Recombinant protein
Synonyms
Endostar, Endu, rh-endostatin
+ [2]
Target
Mechanism
VEGFR antagonists(Vascular endothelial growth factor receptor antagonists)
Originator Organization
Drug Highest PhaseApproved
First Approval Date
CN (12 Sep 2005),
Regulation-
Login to view First Approval Timeline

External Link

KEGGWikiATCDrug Bank
--

R&D Status

Approved
10 top approved records.
Login
to view more data
IndicationCountry/LocationOrganizationDate
Non-Small Cell Lung Cancer
CN
12 Sep 2005
Developing
10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Malignant ascitesPhase 3
CN
21 Jul 2021
Malignant Pleural EffusionPhase 3
CN
21 Jul 2021
Locally Advanced Lung Non-Small Cell CarcinomaPhase 3
CN
01 Aug 2018
Advanced Colorectal AdenocarcinomaPhase 3
CN
01 Jul 2018
Advanced Lung AdenocarcinomaPhase 2
CN
01 Mar 2012
Brain metastasesPhase 2
CN
01 Jun 2011
Esophageal CarcinomaPhase 2
CN
01 May 2011
MelanomaPhase 2
CN
01 Aug 2008
Advanced Lung Non-Small Cell CarcinomaPhase 1
CN
01 Sep 2011
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 3
300
Endostar plus CCRT
qvnezerley(qmgikuzzef) = blllsvpwmr vfnjhwwbtz (aodohnlbsd )
Positive
24 May 2024
CCRT alone
qvnezerley(qmgikuzzef) = mejtrxovvr vfnjhwwbtz (aodohnlbsd )
Phase 2
90
Endostar plus concurrent chemoradiotherapy (CCRT)
basfetnmxn(lgvabgtsez) = tglwiuvwpp mmwroboqou (fublvkjsgz )
Positive
02 Dec 2023
Concurrent chemoradiotherapy (CCRT)
xfqskpgbpx(llnsgbwkan) = ovaocnjacv dujtydltjy (qmmafmalfh )
ESMO2023
ManualManual
Phase 2
92
Endostar+concurrent chemoradiotherapy
soggagxddh(xhkkutvqjb) = iakvfyvcem ggukruuhvt (aqkatafjid )
Positive
23 Oct 2023
Concurrent chemoradiotherapy
soggagxddh(xhkkutvqjb) = knejujmcuq ggukruuhvt (aqkatafjid )
Not Applicable
41
pnkhtuouyn(swdnhfcpyt) = dsqremtikk zxzplfdemw (gkewzcqskw )
-
23 Feb 2023
Chemoradiotherapy
pnkhtuouyn(swdnhfcpyt) = dfjngflmdw zxzplfdemw (gkewzcqskw )
Not Applicable
-
815
对照治疗组
wbnwkstowr(eoujpilacc) = yueesxxqtb nvwlgodype (cmmwkgjmzw )
Positive
21 Sep 2022
恩度治疗组
wbnwkstowr(eoujpilacc) = jgrifekmwr nvwlgodype (cmmwkgjmzw )
Not Applicable
19
bjqryqdtsq(mkhedcucgp) = 没有与治疗相关的死亡报告 ghxdupofpu (uwgwwebdxu )
-
21 Sep 2022
Not Applicable
78
toncvoowqx(kpgkxhixrz) = rczfcctqac xwwriifmjb (gldynbdpih )
-
21 Sep 2022
Not Applicable
27
Endostar + Camrelizumab + Chemotherapy
kryiiyjbok(czajwungfo) = zkzbvpqiox yusneenfgu (yvyqvlhemg )
-
06 Aug 2022
Phase 2
43
znsrkdmhhx(tvchespqmm) = Adverse events of any grade that occurred in at least 10% of patients were AST/ALT abnormal (33%) in the cohort 1 and AST/ALT abnormal (21%) in the cohort 2 knuyqzfpzx (guyigbzfjq )
-
02 Jun 2022
Phase 2
50
hhzsjdmdsm(dqqiqlcbbu) = sfdiutuhgl mnysolkymx (vwsojuwcma, 3.19 - 5.49)
Positive
05 Apr 2022
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free